Jean Liew

Dr. Jean Liew

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2022 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
Richard ConwayRichard Conway
Richard Conway
AMAlyssa A. Grimshaw Mslis
Alyssa A. Grimshaw Mslis
Maximilian KonigMaximilian Konig
Maximilian Konig
MMMichael Putman Md Msci
Michael Putman Md Msci
AMAlí Duarte-García Md Msc
Alí Duarte-García Md Msc
TAthe COVID-19 Global Rheumatology Alliance
the COVID-19 Global Rheumatology Alliance
Objective The relative risk of SARS-CoV-2 infection and COVID-19 disease severity among people with rheumatic and musculoskeletal diseases (RMD) compared to those without RMD remains uncertain. We sought to quantify the risk for SARS-CoV-2 infection and describe clinical outcomes of COVID-19 in people with RMD. Methods A systematic literature review was conducted using 14 databases from January 1st, 2019 to February 13th, 2021. We included observational studies and experimental trials in RMD patients reporting comparative rates of SARS-CoV-2 infection, hospitalization, oxygen supplementation/ICU admission/mechanical ventilation, or mortality attributed to COVID-19. Methodological quality was evaluated using the Joanna Briggs Institute Critical Appraisal Tools or the Newcastle-Ottawa scale. Risk ratios (RRs) and odds ratios (ORs) were calculated, as applicable for each outcome, using the Mantel-Haenszel formula with random effect models. Results Of 5799 abstracts screened, 100 studies met criteria for inclusion in the systematic review and 54/100 had a low risk-of-bias. Among studies included in the meta-analyses, we found an increased prevalence of SARS-CoV-2 infection in people with RMD (RR 1.53 (95%CI 1.16, 2.01)) compared with the general population. Odds of hospitalization, ICU admission, and mechanical ventilation were similar in patients with and without RMD, whereas odds of mortality was increased (OR 1.74 (95%CI 1.08, 2.80)). A smaller number of studies reported adjusted risk for outcomes and variably demonstrated increased risk for no difference in risk. Conclusion Patients with RMDs had higher rates of SARS-CoV-2 infection and increased odds of mortality.

15 January 2013 in Journal of Bacteriology
Verified
Journal Article
Closed access
AWAimee K. Wessel
Aimee K. Wessel
JLJean Liew
Jean Liew
TKTaejoon Kwon
Taejoon Kwon
EMEdward M Marcotte
Edward M Marcotte
MWMarvin Whiteley
Marvin Whiteley
Gram-negative bacteria produce outer membrane vesicles (OMVs) that package and deliver proteins, small molecules, and DNA to prokaryotic and eukaryotic cells. The molecular details of OMV biogenesis have not been fully elucidated, but peptidoglycan-associated outer membrane proteins that tether the outer membrane to the underlying peptidoglycan have been shown to be critical for OMV formation in multiple Enterobacteriaceae . In this study, we demonstrate that the peptidoglycan-associated outer membrane proteins OprF and OprI, but not OprL, impact production of OMVs by the opportunistic pathogen Pseudomonas aeruginosa . Interestingly, OprF does not appear to be important for tethering the outer membrane to peptidoglycan but instead impacts OMV formation through modulation of the levels of the Pseudomonas quinolone signal (PQS), a quorum signal previously shown by our laboratory to be critical for OMV formation. Thus, the mechanism by which OprF impacts OMV formation is distinct from that for other peptidoglycan-associated outer membrane proteins, including OprI.

1 June 2018 in Best Practice & Research Clinical Rheumatology
Verified
Journal Article
Closed access
JLJean Liew
Jean Liew
SRSofia Ramiro
Sofia Ramiro
LGLianne S. Gensler
Lianne S. Gensler

2 February 2021 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
MGMilena A. Gianfrancesco
Milena A. Gianfrancesco
LLLiza A. Leykina
Liza A. Leykina
ZIZara Izadi
Zara Izadi
TTTiffany Taylor
Tiffany Taylor
JSJeffrey A. Sparks
Jeffrey A. Sparks
TAthe COVID‐19 Global Rheumatology Alliance
the COVID‐19 Global Rheumatology Alliance
Objective: Racial/ethnic minorities experience more severe outcomes of coronavirus disease 2019 (COVID‐19) in the general US population. This study was undertaken to examine the association between race/ethnicity and COVID‐19 hospitalization, ventilation status, and mortality in people with rheumatic disease.Methods: US patients with rheumatic disease and COVID‐19 were entered into the COVID‐19 Global Rheumatology Alliance physician registry between March 24, 2020 and August 26, 2020 were included. Race/ethnicity was defined as White, African American, Latinx, Asian, or other/mixed race. Outcome measures included hospitalization, requirement for ventilatory support, and death. Multivariable regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) adjusted for age, sex, smoking status, rheumatic disease diagnosis, comorbidities, medication use prior to infection, and rheumatic disease activity.Results: A total of 1,324 patients were included, of whom 36% were hospitalized and 6% died; 26% of hospitalized patients required mechanical ventilation. In multivariable models, African American patients (OR 2.74 [95% CI 1.90–3.95]), Latinx patients (OR 1.71 [95% CI 1.18–2.49]), and Asian patients (OR 2.69 [95% CI 1.16–6.24]) had higher odds of hospitalization compared to White patients. Latinx patients also had 3‐fold increased odds of requiring ventilatory support (OR 3.25 [95% CI 1.75–6.05]). No differences in mortality based on race/ethnicity were found, though power to detect associations may have been limited.Conclusion: Similar to findings in the general US population, racial/ethnic minorities with rheumatic disease and COVID‐19 had increased odds of hospitalization and ventilatory support. These results illustrate significant health disparities related to COVID‐19 in people with rheumatic diseases. The rheumatology community should proactively address the needs of patients currently experiencing inequitable health outcomes during the pandemic.

23 April 2022 in Rheumatology
Verified
Journal Article
Open access
PDF file
LRLisa Rider
Lisa Rider
CPChristine G Parks
Christine G Parks
JWJesse Wilkerson
Jesse Wilkerson
ASAdam I Schiffenbauer
Adam I Schiffenbauer
Richard KwokRichard Kwok
Richard Kwok
FMFrederick W Miller
Frederick W Miller
To examine the frequency of, and risk factors for, disease flare following COVID-19 vaccination in patients with systemic rheumatic disease (SRD). An international study was conducted from 2 April to 16 August 2021, using an online survey of 5619 adults with SRD for adverse events following COVID-19 vaccination, including flares of disease requiring a change in treatment. We examined risk factors identified a priori based on published associations with SRD activity and SARS-CoV-2 severity, including demographics, SRD type, comorbidities, vaccine type, cessation of immunosuppressive medications around vaccination and history of reactions to non-COVID-19 vaccines, using multivariable logistic regression. Flares requiring a change in treatment following COVID-19 vaccination were reported by 4.9% of patients. Compared with rheumatoid arthritis, certain SRD, including systemic lupus erythematosus (OR 1.51, 95% CI 1.03, 2.20), psoriatic arthritis (OR 1.95, 95% CI 1.20, 3.18) and polymyalgia rheumatica (OR 1.94, 95% CI 1.08, 2.48) were associated with higher odds of flare, while idiopathic inflammatory myopathies were associated with lower odds for flare (OR 0.54, 95% CI 0.31–0.96). The Oxford-AstraZeneca vaccine was associated with higher odds of flare relative to the Pfizer-BioNTech vaccine (OR 1.44, 95% CI 1.07, 1.95), as were a prior reaction to a non-COVID-19 vaccine (OR 2.50, 95% CI 1.76, 3.54) and female sex (OR 2.71, 95% CI 1.55, 4.72). SRD flares requiring changes in treatment following COVID-19 vaccination were uncommon in this large international study. Several potential risk factors, as well as differences by disease type, warrant further examination in prospective cohorts.

2 July 2020 in Expert Review of Clinical Immunology
Verified
Journal Article
Closed access
SSSebastian E. Sattui
Sebastian E. Sattui
JLJean Liew
Jean Liew
EGElizabeth R. Graef
Elizabeth R. Graef
MMMina Musashi
Mina Musashi
FBFrancis Berenbaum
Francis Berenbaum
JSJeffrey A. Sparks
Jeffrey A. Sparks
Several months into the COVID-19 pandemic, safe and effective treatments against this global health disaster have yet to be identified. Clinical research trials around the world are underway testin...